SCHEDULE 13G: Armistice Capital and Steven Boyd Disclose 9.99% Stake in XORTX Therapeutics
Beneficial Ownership Disclosure
Armistice Capital, LLC and Steven Boyd have jointly filed a Schedule 13G, reporting beneficial ownership of 9.99% of XORTX Therapeutics Inc.'s common shares as of December 31, 2024.
Summary
- Armistice Capital, LLC and Steven Boyd (collectively, the "Reporting Persons") have filed a Schedule 13G with the U.S. Securities and Exchange Commission (SEC).
- The filing indicates beneficial ownership of 346,807 common shares of XORTX Therapeutics Inc., which represents 9.99% of the total class of common shares.
- Both Armistice Capital, LLC and Steven Boyd hold shared voting power and shared dispositive power over these 346,807 shares.
- Armistice Capital, LLC serves as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares.
- Steven Boyd is identified as the managing member of Armistice Capital, LLC.
- The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: Neutral. This is a factual disclosure of an ownership stake and does not contain information that would inherently indicate positive or negative sentiment regarding the issuer's performance or prospects.
Future Outlook
NA
Industry Context
This filing is a routine disclosure of an institutional ownership stake and does not provide broader industry context or trends.
Stakeholder Impact
- This filing indicates a significant institutional investor, Armistice Capital, LLC, holds a substantial stake, which could be viewed positively by other investors as a vote of confidence.
- The filing clarifies that the stake is held in the ordinary course of business and not for the purpose of influencing control, which may reassure existing management and shareholders.
Key Dates
| Date | Description |
|---|---|
| 12/31/2024 | Date of event which requires filing of this statement (end of reporting period). |
| 02/14/2025 | Date of filing of this Schedule 13G. |
Keywords
XORTX Therapeutics Inc., Armistice Capital LLC, Steven Boyd, Schedule 13G, SEC filing, beneficial ownership, common shares, institutional investment, equity stake, investment management
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.